Filing Flows › Seres Therapeutics (MCRB) › Q1 2026
Seres Therapeutics (MCRB) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 5, 2026
Seres Therapeutics (MCRB) reported revenue of $358K for the first quarter 2026 (Q1 2026) and -18% from the quarter before.
Seres Therapeutics, Q1 2026: revenue $358K, net loss $19.9M, operating cash flow −$16.4M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $358K | -18% | — |
| Operating profit | −$20.9M | — | — |
| Net earnings | −$19.9M | — | — |
| Operating cash flow | −$16.4M | — | — |
What changed
Revenue was $358K in Q1 2026, down 18% from the previous quarter.
Operating costs exceeded revenue by $20.9M, an operating margin of -5839.9%. The quarter ended with a net loss of $19.9M, wider than the previous quarter's $15.3M loss.
Operating cash flow was −$16.4M. Non-cash charges added back $781K of depreciation and amortization and $1.8M of share-based compensation. Working capital and other items added $1.0M.
Questions
What was Seres Therapeutics' revenue in the first quarter 2026?
Seres Therapeutics (MCRB) reported revenue of $358K for the first quarter 2026 (Q1 2026) and -18% from the quarter before.
Source: Seres Therapeutics 10-Q on SEC EDGAR.